NasdaqGS - Nasdaq Real Time Price ? USD Trinity Biotech plc (TRIB) Follow Compare 1.2800 -0.0200 (-1.54%) As of 2:15 PM EST. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Trinity Biotech PLC (TRIB) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... Trinity Biotech PLC (TRIB) reports a 3% revenue increase and outlines strategic initiatives for future growth and profitability. GuruFocus.com ? 5 days ago TRIB -1.54% Trinity Biotech Announces Q3 2024 Financial Results Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately $75 million by Q2 2025 Reiterates guidance to achieve 2024 sales revenue for TrinScreen HIV of approximately $10 million DUBLIN, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (N GlobeNewswire ? 6 days ago TRIB -1.54% Trinity Biotech to Announce Q3 2024 Financial Results Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ETDUBLIN, Ireland, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the third quarter 2024 on Friday, November 15, 2024 and host a conference call at 10:00 AM ET. Conference Call Dial-In & Webcast Information Date:Friday, Nov GlobeNewswire ? 7 days ago TRIB -1.54% Trinity Biotech Regains Compliance with Nasdaq Listing Requirements DUBLIN, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that on November 6, 2024, it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum market value of publicly held shares (“MVPHS”) requirement under Nasdaq Listing Rule 5450( GlobeNewswire ? 14 days ago TRIB -1.54% Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic investment in Novus Diagnostics, a company pioneering a rapid sepsis testing platform. This investment will accelerate the development and commercialization of Novus’ groundbreaking point-of-care diagnostic solutions, including its 15-minute bloodstream infe GlobeNewswire ? 27 days ago TRIB -1.54% Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the acquisition of EpiCapture Limited, a company developing a non-invasive test for monitoring the risk of aggressive prostate cancer. This acquisition marks Trinity Biotech’s strategic expansion into the oncology diagnostics market. Prostate cancer is the most common n GlobeNewswire ? 27 days ago TRIB -1.54% Trinity Biotech PLC (TRIB) Q2 2024 Earnings Call Highlights: Strong Point-of-Care Growth Amidst ... Trinity Biotech PLC (TRIB) reports a 14% revenue increase with significant strides in point-of-care sales and operational efficiency. GuruFocus.com ? last month TRIB -1.54% Trinity Biotech Shares Surge on Positive Pre-Pivotal Clinical CGM Trial TRIB announces positive results from its pre-pivotal clinical European trial for a next-gen continuous glucose monitor, setting the stage for further development in 2025. Zacks ? last month TRIB -1.54% RMTI AVAH Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the successful completion of its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor (CGM) technology. The study assessed the analytical performance of CGM technology enhancements implemented by Trinity Biotech since acquiring t GlobeNewswire ? last month TRIB -1.54% Trinity Biotech Acquires Preeclampsia Prediction Firm Trinity Biotech (TRIB) has released an update. Trinity Biotech has acquired Metabolomics Diagnostics, an Irish deep-tech company known for its preeclampsia risk prediction test, PrePsia, which is expected to launch in the U.S. in 2025 through Trinity’s Immco reference lab. This strategic acquisition enhances Trinity’s diagnostics platform with advanced machine learning and bioinformatics for maternal health, aiming to address the urgent clinical needs in this sector. The transaction, valued at a TipRanks ? last month TRIB -1.54% Trinity Biotech's Stock Rises After Acquisition of Metabolomics TRIB acquires Metabolomics Diagnostics, expanding its platform with cutting-edge tech to enhance diagnostics in maternal health and diabetes management. Zacks ? last month TRIB -1.54% UHS Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market -Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women- -The PrePsia test can predict preeclampsia risk as early as in the 12th week of pregnancy, allowing for early interventions to prevent serious health issues for mothers and their babies- -PrepSia will be commercialized in the U.S. market in 2025 through Trinity Biotech’s New York-based Immco reference l GlobeNewswire ? last month TRIB -1.54% Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer DUBLIN, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on its development and global launch plans for its next generation Continuous Glucose Monitoring (“CGM”) technology. CGMs are small patch-like wearable medical devices that use biosensor wires under the skin to measure glucose in real-time. These devices are i GlobeNewswire ? 2 months ago TRIB -1.54% Will Trinity Biotech Stock Gain From Its Latest Patent Process? TRIB announces updates on its European patented process. The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology. Zacks ? 2 months ago TRIB -1.54% BSX Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology DUBLIN, Ireland, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on the continued development of its glucose biosensor technology. Earlier this year Trinity Biotech was granted a European patent (EP3703565) for a novel method that enhances the performance of an indwelling sensor, such as a glucose biosensor. Recent GlobeNewswire ? 2 months ago TRIB -1.54% Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Adrian Donohue as Chief Commercial Officer. Mr. Donohue brings more than 25 years of experience in the sales and marketing of healthcare products. John Gillard, President and Chief Executive Officer of Trinity Biotech, said, “We are resolute GlobeNewswire ? 2 months ago TRIB -1.54% Sector Update: Health Care Stocks Edge Higher in Late Afternoon Sector Update: Health Care Stocks Edge Higher in Late Afternoon PREMIUM MT Newswires ? 2 months ago TRIB -1.54% PODD LLY Why Is Clinical Diagnostics Focused Trinity Biotech Stock Trading Higher On Tuesday? Tuesday, Trinity Biotech plc (NASDAQ:TRIB) stock is trading higher with a session volume of 14.32 million versus the average volume of 118.9K as per data from Benzinga Pro. The company received substantial additional orders for TrinScreen HIV. Due to this demand and the scaling of production capacity, the company is now increasing its expected 2024 sales revenue for TrinScreen HIV to approximately $10 million, up from $8 million. President and Chief Executive Officer of Trinity Biotech, John Gil Benzinga ? 2 months ago TRIB -1.54% Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales DUBLIN, Ireland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV. As a result of this strong demand and the successful scaling of production capacity, the Company is now increasing its expected 2024 sales revenue for TrinScreen HIV to approximately $10 mil GlobeNewswire ? 2 months ago TRIB -1.54% Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of David Ouston as Biosensor Marketing Director. Mr. Ouston brings a wealth of commercial experience driving the growth of glucose monitoring devices at large, established companies across global markets. John Gillard, President and Chief Executive Offic GlobeNewswire ? 2 months ago TRIB -1.54% Performance Overview Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is MSCI WORLD Return TRIB MSCI WORLD YTD -40.47% +18.49% 1-Year -34.36% +24.96% 3-Year -86.94% +16.62%
